Prescription Drug Freight Fraud Report, June 2025

What if your tirzepatide shipment came from a Brazilian beauty clinic? Or a vial of semaglutide was manufactured, supposedly, at a Costco in Toronto? In April and May 2025, dozens of shipments of semaglutide, tirzepatide, apixaban, and antibiotics entered the U.S. from facilities that aren’t in the FDA’s drug manufacturing database. These aren’t low-volume personal-use…

[...]

Pill press update: January through June 2025

Pill presses and molds are used to make fake pills with deadly consequences thousands of people every year. The number of Americans that take fake pills annually without a fatal event is even higher. Read our January through June 2025 report covering pill press seizures, policy developments, and legislation.

[...]

The End of GLP-1 Compounding

Federally-registered compounding facilities stopped making tirzepatide on May 22. This transition is significant for patients, and we at PSM think there are four things you should be watching for.

[...]

Handout: Illegal ingredients linked to knockoff weight loss drugs pouring in from foreign sources

Compounded versions of GLP-1 injectable treatments for diabetes and obesity have surged in popularity despite a lack the safety and efficacy assurances. The FDA has warned that these knockoff versions sometimes contain illicit semaglutide or tirzepatide—the active pharmaceutical ingredients (APIs) in weight loss drugs. Working with George Karavetsos, former director of FDA’s Office of Criminal…

[...]